EGF (Epidermal Growth Factor)vsResveratrol

EGF binds EGFR/ErbB1 on keratinocytes and fibroblasts, triggering dimerization and autophosphorylation. Activates MAPK/ERK (Ras-Raf-MEK-ERK) and PI3K/AKT pathways, promoting proliferation, migration (actin reorganization, focal adhesion turnover), and differentiation. Upregulates cyclin D1, inhibits p27. Stimulates fibroblast collagen types I/III and hyaluronic acid via HAS2. In wound healing, accelerates re-epithelialization via keratinocyte migration and reduces scarring via TGF-beta modulation. For anti-aging, promotes cellular renewal and extracellular matrix production. Theoretical cancer concern from EGFR's growth role — topical EGF has not been shown to penetrate to basal layer or systemic circulation significantly.

Resveratrol activates SIRT1 (sirtuin 1), a NAD+-dependent deacetylase that deacetylates histones and non-histone targets including p53, FOXO transcription factors, and NF-κB, regulating cellular stress response, DNA repair, autophagy, and inflammatory pathways in keratinocytes and fibroblasts. It scavenges superoxide anion, hydroxyl radical, and metal-induced free radicals through its phenolic hydroxyl groups. Resveratrol inhibits NF-κB nuclear translocation and downstream cytokine production (TNF-α, IL-1β, IL-6), reducing UV-induced inflammation. It inhibits tyrosinase (mild brightening), matrix metalloproteinase-9 (MMP-9, gelatinase B) to prevent collagen and elastin breakdown, and AP-1 (c-Fos/c-Jun) to reduce photoaging-related gene expression. It may also activate Nrf2, upregulating antioxidant enzymes (HO-1, NQO1). Topical application achieves higher skin tissue concentrations than oral supplementation due to first-pass metabolism. Stability is improved in anhydrous or encapsulated formulations.